Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Lexicon Pharmaceuticals (Nasdaq: LXRX) shares fell as much as 14% in intraday trading on disappointing results of its rheumatoid arthritis drug test.

So what: The drug, LX2931, showed a positive response in high doses, but low doses showed a response rate lower than a placebo. The company said it was happy with the safety profile and is planning to start discussions with potential partners.

Now what: Lexicon is counting on LX2931 to perform better than we have seen, and despite the company moving forward, I am concerned with today's results. After knocking shares down early, the stock has come back steadily throughout the day, indicating that investors are still willing to bet on the company. Still, I don't see today as a buying opportunity and will stay away until I see some positive results from Lexicon.

Interested in more info on Lexicon Pharmaceuticals? Add it to your watchlist.